April 22nd 2024
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
CAR T-Cell Therapies for Hematologic Malignancies Moving Toward the Clinic
August 16th 2017Development of chimeric antigen receptor T-cell therapies is in the works for both hematologic malignancies and solid tumors, but the most promising results to date have been seen with CD19-targeted CAR T cells in the treatment of B-cell acute lymphoblastic leukemia.
Read More
CPX-351 Approved by FDA for 2 Types of AML
August 3rd 2017CPX-351 (Vyxeos), a fixed-combination of daunorubicin and cytarabine, has been approved by the FDA for adult patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), based on an improvement in overall survival (OS) in a phase III study.
Read More
Enasidenib Approved by FDA for IDH2-Mutated AML
August 1st 2017Enasidenib (Idhifa) has been approved by the FDA as a treatment for patients with relapsed or refractory <em>IDH2</em>-mutated acute myeloid leukemia (AML), based on findings from a phase I/II study. A companion diagnostic, the RealTime IDH2 Assay, was also approved for the detection of the <em>IDH2</em> mutation.
Read More
Venetoclax Granted Breakthrough Therapy Designation by FDA for AML Subpopulation
July 31st 2017The FDA has granted breakthrough therapy designation to venetoclax (Venclexta) for use in combination with low dose cytarabine (LDAC) in treatment-naïve elderly patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, according to Roche, which is codeveloping the BCL-2 inhibitor with AbbVie.
Read More
Midostaurin Granted Recommendation for EU Approval in AML
July 24th 2017Midostaurin (Rydapt) has been recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to treat adults with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation–positive.
Read More
ODAC Recommends Approval of Tisagenlecleucel for Relapsed/Refractory Pediatric ALL
July 13th 2017The Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.
Read More
Gemtuzumab Ozogamicin Recommended for Approval by ODAC for Newly Diagnosed AML
July 12th 2017In a 6-1 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in favor of approving gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia.
Read More
Blinatumomab Granted Full Approval by the FDA for B-cell Precursor ALL
July 12th 2017Blinatumomab (Blincyto) has been granted a full approval by the FDA as a treatment for adults and children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, regardless of Philadelphia chromosome status.
Read More
Results for the Combination of Ublituximab and Ibrutinib in CLL
July 7th 2017Jeff Sharman, MD, discusses findings of the phase III GENUINE study, which explored the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).
Watch
Subcutaneous Rituximab Approved by FDA for Blood Cancers
June 22nd 2017Subcutaneous rituximab has been approved by the FDA for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated CLL.
Read More
ODAC Hearing Scheduled to Discuss CTL019 in Relapsed/Refractory B-cell ALL
June 7th 2017The FDA has scheduled a public hearing of its Oncologic Drugs Advisory Committee (ODAC) to address a biologics license application (BLA) for tisagenlecleucel-T (CTL019) for patients aged 3 to 25 years with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). The hearing is planned for July 12, 2017.
Read More
Comparing Bosutinib Versus Imatinib in Newly Diagnosed CML
June 6th 2017Jorge Cortes, MD, deputy chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses initial results from the BFORE trial, which is exploring bosutinib (Bosulif) versus imatinib (Gleevec) for newly diagnosed chronic myeloid leukemia.
Watch
Midostaurin Approved by FDA for AML
April 28th 2017Midostaurin (Rydapt) has been approved by the FDA for the treatment of adult patients with newly diagnosed <em>FLT3</em>-positive acute myeloid leukemia (AML) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Read More
Study Finds Longer Survival Seen With Ibrutinib Discontinuation Due to Toxicities
April 19th 2017Patients with chronic lymphocytic leukemia (CLL) who stopped treatment with ibrutinib due to toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation, according to the results of a recently published study.
Read More
Finding a Quick, Durable Therapy for Elderly Patients With AML is the Holy Grail, Expert Says
April 12th 2017Andrew Wei, MBBS, PhD, discusses a study which explored the safety and efficacy of the novel BCL-2 inhibitor venetoclax in combination with low-dose cytarabine chemotherapy for treatment-naïve patients over the age of 65 with AML.
Read More
Exploiting DNA Repair Deficiency in IDH-Mutant Brain Tumors Likely an Improved Treatment Strategy
April 6th 2017Mutations in isocitrate dehydrogenase 1 and 2 (<em>IDH1/2</em>) are not the mutations commonly found in cancer cells, according to a presentation from the 2017 AACR Annual Meeting.
Read More
Exploring Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With AML
April 6th 2017Sudipto Mukherjee, MD, assistant staff, Gaussig Cancer Institute, Cleveland Clinic, discusses a study exploring eltrombopag to enhance platelet count recovery in elderly patients with acute myeloid leukemia (AML).
Watch
sBLA for Full Approval of Blinatumomab in ALL Granted FDA's Priority Review
March 30th 2017The FDA has granted a priority review to a supplemental biologics license application (sBLA) supporting the conversion of the accelerated approval of blinatumomab (Blincyto) to a full approval as a treatment for patients with Philadelphia chromosome-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
Read More